Prevail Breakthrough PM
Natural health product licensed in Canada
- Licence holder
- Valentus, Inc.
- NPN or DIN-HM
- 80078796
- Status
- Active licence
- Licence date
- 29 June 2017
- Revision date
- 30 November 2021
- Form
- Poudre pour solution
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Glycyrrhiza glabra L.: La portion journalière recommandée ne doit pas conduire à une ingestion d'acide glycyrrhizinique supérieure à 100 mg. L'étiquetage doit comporter un avertissement avec la teneur suivante: "Ne pas utiliser pendant plus de 6 semaines sans avis médical." L'étiquetage doit comporter un avertissement déconseillant l'emploi chez les enfants.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Citrus aurantium L.: La quantité ingérée de p-synéphrine doit être inférieure à 20 mg par dose journalière recommandée. L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants, aux femmes enceintes ou allaitantes et en cas de traitement anti-hypertenseur. La caféine et les sources de caféine ne sont pas autorisées dans les compléments alimentaires contenant Citrus aurantium L.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Silybum marianum Source : Graine(s) Potency : 80 % Silymarin | 50 milligramme | Not calculated |
| Taraxacum officinale Source : Racine Extract : Matériel brut sec Extraction ratio : 4:1 Dry plant equivalent : 3,000 milligramme | 750 milligramme | Not calculated |
| Phyllanthus emblica Source : Fruit | 133 milligramme | Not calculated |
| Terminalia chebula Source : Fruit | 133 milligramme | Not calculated |
| Terminalia bellirica Source : Fruit | 133 milligramme | Not calculated |
| Glycyrrhiza glabra Source : Racine | 100 milligramme | Not calculated |
| Uncaria tomentosa Source : Écorce de racine | 50 milligramme | Not calculated |
| Uncaria tomentosa Source : Écorce (tige) | 50 milligramme | Not calculated |
| Handroanthus heptaphyllus Source : Stem bark - inner | 500 milligramme | Not calculated |
| Handroanthus heptaphyllus Source : Ecorce de racine (intérieur) | 500 milligramme | Not calculated |
| Citrus aurantium Source : Pelure (fruit) | 500 milligramme | Not calculated |
| Inuline Source : Cichorium intybus - racine | 300 milligramme | Not calculated |
Non-medicinal ingredients
Not provided.
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Portion(s) | 1 Tous les jours |
Uses authorised in Canada
Traditionally used in Herbal Medicine as an alternative to help relieve dermatological conditions. Traditionally used in Herbal Medicine to help treat digestive disturbances (dyspepsia).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
If you have liver or gall bladder diseases, and/or intestinal obstruction, consult a health care practitioner prior to use. If symptoms persist or worsen, consult a health care practitioner. If you have abdominal pain, nausea, fever or vomiting, consult a health care practitioner prior to use. If you experience abdominal pain, cramps, spasms and/or diarrhoea while using this product, reduce dose or discontinue use. Consult a health care practitioner prior to use if you are taking anticoagulant or antihypertensive medication. Consult a health care practitioner prior to use if you suffer from an immune system disorder (e.g. Crohn's disease, myasthenia gravis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, HIV/AIDS, etc.), cancer, asthma, are taking immunosuppressants or have severe allergies.
- Contre-indications
Do not use if you are taking thiazide diuretics, cardiac glycosides, corticosteroids, stimulant laxatives or other medications which may aggravate electrolyte imbalance. Do not use if you have hypokalemia, high blood pressure, or a kidney or cardiovascular disorder. Do not use if you are pregnant or breastfeeding.
- Effets indésirables connus
If hypersensitivity or allergy occurs, discontinue use. Laxative effect may occur, in which case, discontinue use.
Source
Official Health Canada record, licence 80078796
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2021. Photograph the packaging to check whether it has changed. Photograph the packaging